Drug intelligence / Profile preview

AP10

Development stage: Preclinical
Lead developer: Aprogen
Modality: RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics

Overview

AP10 is a G-quadruplex DNA aptamer that has been designed in silico to target the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. This aptamer is being investigated for its potential in both the diagnosis and therapeutic intervention of SARS-CoV-2 infection by blocking the virus's ability to bind to host cells.

Targets

CD43 (CD43 antigen)

Beyond the preview

Go deeper on AP10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AP10.

Explore the full profile